Staphylococcus Aureus Infection
Conditions
Brief summary
Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine. This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an experimental recombinant staphylococcus aureus vaccine. The study will be carried out following a dose-escalation method from the low dosage to the high dosage, i.e. the higher dosage vaccine could only be administrated after the first seven-day safety of the lower dosage vaccine is confirmed after safety observation.
Interventions
BIOLOGICALLow dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
BIOLOGICALMiddle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
BIOLOGICALHigh dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
BIOLOGICALPlacebo
Sponsors
Chengdu Olymvax Biopharmaceuticals Inc.
Third Military Medical University
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years). * Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period. * Able to understand the content of informed consent and willing to sign the informed consent. * Able to complete the diary card independently. * For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study. * Axillary temperature ≤37.0°C.
Exclusion criteria
First Immunization exclusion standard: * Prior receipt of Staphylococcus aureus vaccine * Any confirmed Staphylococcus aureus infection disease in the past 12 month. * History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index. * Prior blood donation or Blood loss over 400ml in the last 3 months; * Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed. * History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain. * Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease. * Taking immunoglobulins and/or any blood products within the last 12 months. * Asplenia, functional asplenia or asplenia caused by any situation or splenectomy. * Any acute disease or acute attack of chronic disease in last 7 days. * History of thyroidectomy or thyroid disease requiring treatment in the last 12 months. * Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment) * Participation in another research study involving receipt of an investigational product in the last 30 days. * Woman who is breast-feeding. * Prior administration of attenuated vaccine in last 28 days. * Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days. * Current anti-tuberculosis prophylaxis or therapy * Any other conditions may compromise the safety or availability of participants in the judgment of the investigator. Following Immunization exclusion standard: * Any grade 3 or more serious adverse reaction happen since the last vaccination. * Other condition violates the inclusion criteria or meets the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of injection site adverse reactions after vaccination | within 21 days after the vaccination | Occurrence of solicited injection site adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine |
| Occurrence of systematic adverse reactions after vaccination | within 21 days after the vaccination | Occurrence of solicited systematic adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of the blood routine after vaccination. | day 0-17 after the vaccination | Changes of the blood routine after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. |
| Occurrence of unsolicited adverse reactions after vaccination. | within 42 days after the vaccination | Occurrence of unsolicited adverse reactions within 42 days after vaccination with the Recombinant Staphylococcus aureus vaccine |
| Changes of the blood biochemistry after vaccination. | day 0-17 after the vaccination | Changes of the blood biochemistry after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. |
| Occurrence of serious adverse events after the vaccination. | within 6 months after the vaccination | Occurrence of serious adverse events within 6 months after the vaccination with the Recombinant Staphylococcus aureus vaccine |
| Geometric mean titre against specific antigens | within 6 months after the vaccination | Geometric mean titre measured at day 0, 7, 14, 21, 42 and month 3, 6. |
| Geometric mean fold increase against specific antigens | within 6 months after the vaccination | Geometric mean fold increase measured at day 7, 14, 21, 42 and month 3, 6. |
| Positive conversion rate of serum against specific antigens | within 6 months after the vaccination | Positive conversion rate of serum measured at day 7, 14, 21, 42 and month 3, 6. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination. | within 6 months after the vaccination | Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination with the Staphylococcus aureus vaccine at day at day 3, 7, 10, 14, 17, 21, 42 and month 3, 6. |
| Specific functional antibody responses to the Staphylococcus aureus vaccine | within 6 months after the vaccination | Specific functional antibody responses to the Staphylococcus aureus vaccine at day 7, 14, 21, 42 and month 3, 6. |
| Specific T cell immune responses to the Staphylococcus aureus vaccine. | within 6 months after the vaccination | Specific T cell immune responses to the Staphylococcus aureus vaccine at day at day7, 14, 21, 42 and month 3, 6 measured by ELISpot. |
Countries
China
Outcome results
None listed